Top > Search of International Patents > CLEC-2 ANTAGONIST, PLATELET AGGREGATION INHIBITOR, ANTITHROMBOTIC AGENT, ANTIMETASTATIC AGENT, ANTIARTHRITIC AGENT, COMPOUND HAVING PORPHYRIN SKELETON, AND METHOD FOR PRODUCING SAME

CLEC-2 ANTAGONIST, PLATELET AGGREGATION INHIBITOR, ANTITHROMBOTIC AGENT, ANTIMETASTATIC AGENT, ANTIARTHRITIC AGENT, COMPOUND HAVING PORPHYRIN SKELETON, AND METHOD FOR PRODUCING SAME

Foreign code F170009129
File No. (S2016-0297-N0)
Posted date Jul 20, 2017
Country WIPO
International application number 2017JP000059
International publication number WO 2017119417
Date of international filing Jan 4, 2017
Date of international publication Jul 13, 2017
Priority data
  • P2016-000267 (Jan 4, 2016) JP
Title CLEC-2 ANTAGONIST, PLATELET AGGREGATION INHIBITOR, ANTITHROMBOTIC AGENT, ANTIMETASTATIC AGENT, ANTIARTHRITIC AGENT, COMPOUND HAVING PORPHYRIN SKELETON, AND METHOD FOR PRODUCING SAME
Abstract Disclosed is a CLEC-2 antagonist comprising a compound represented by either general formula (1) or general formula (2). (In general formula (1), M represents H2 or one of Group 2 to 12 elements, R1 represents a vinyl group or a 1-hydroxyethyl group, and X represents a Group 1 element.) (In general formula (2), M represents H2 or one of Group 2 to 12 elements, and R2 represents a phenyl group, a sulfophenyl group, a carboxyphenyl group, or a 1-methylpyridinium-4-yl group.)
Scope of claims [claim1]
1. The below-mentioned general formula (1) and the below-mentioned general formula the CLEC-2 competition medicine which features that it consists of the chemical compound where each with (2) is displayed.
(General system (1))
(However, the aforementioned general system (1) in, M H [2] and displays either of the 2-12 family element, R (1) the vinyl basis and 1 - displays either of the hydroxyethyl basis, X displays the 1st family element.)
(General system (2))
(However, the aforementioned general system (2) in, M H [2] and displays either of the 2-12 family element, R (2) phenyl group and sulfonic phenyl group, karubokishihueniru and 1 - mechirupirijiniumu - 4 - displays either of the iru basis.)
[claim2]
2. The aforementioned general system the chemical compound which is displayed with (1), the below-mentioned general formula (1-A) and the below-mentioned general formula (1-B) in the claim 1 which is the chemical compound which is displayed with in each case the CLEC-2 competition medicine of statement.
(General system (1-A))
(However, the aforementioned general system (1-A) in, M H [2], displays either Co, Zn, Ni and Pd, X displays the 1st family element.)
(General system (1-B))
(However, the aforementioned general system (1-B) in, M H [2], displays either Co, Zn and Cu.)
[claim3]
3. The aforementioned general system (1-B) with the chemical compound which is displayed, in the claim 2 which is the chemical compound which is displayed with the below-mentioned structural formula B4 the CLEC-2 competition medicine of statement.
(Structural formula B4)
[claim4]
4. The aforementioned general system the chemical compound which is displayed with (2), from the claim 1 which is the chemical compound which is displayed with the below-mentioned structural formula C1 in either of 3 the CLEC-2 competition medicine of statement.
(Structural formula C1)
[claim5]
5. The blood platelet cohesion inhibiter which features that from claim 1 it consists of the CLEC-2 competition medicine of statement in either of 4.
[claim6]
6. The anti- thrombus medicine which features that from claim 1 it consists of the CLEC-2 competition medicine of statement in either of 4.
[claim7]
7. The anti- transfer medicine which features that from claim 1 it consists of the CLEC-2 competition medicine of statement in either of 4.
[claim8]
8. The anti- arthritis medicine which features that from claim 1 it consists of the CLEC-2 competition medicine of statement in either of 4.
[claim9]
9. The below-mentioned general formula (1-A) and the below-mentioned general formula (1-B) the chemical compound which features that it is displayed with in each case.
(General system (1-A))
(However, the aforementioned general system (1-A) in, M displays either Co, Zn, Ni and Pd, X displays the 1st family element.)
(General system (1-B))
(However, the aforementioned general system (1-B) in, M displays either Co, Zn and Cu.)
[claim10]
10. The salt and metal acetate of the protoporphyrin, when either dimethyl sulfoxide and acetic acid, under existing of the water, 1 hour -30 hours reacting with the 70.deg.C-95.deg.C, the below-mentioned general formula (1-A) with production method of the chemical compound which features that the process which obtains the chemical compound which is displayed is included.
(General system (1-A))
(However, the aforementioned general system (1-A) in, M displays either Co, Zn, Ni and Pd, X displays the 1st family element.)
[claim11]
11. Under each existing of methanol and acetic acid, 5 hour -30 hours reacting the hematoporphyrin and metal acetate, with the 15.deg.C-30.deg.C, the below-mentioned general formula (1-B) with production method of the chemical compound which features that the process which obtains the chemical compound which is displayed is included.
(General system (1-B))
(However, the aforementioned general system (1-B) in, M displays either Co, Zn and Cu.)
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • UNIVERSITY OF YAMANASHI
  • Inventor
  • INOUE KATSUE
  • OSADA MAKOTO
  • KOJIMA SOICHI
  • SAITO TAMIO
  • SASAKI TOMOYUKI
  • SHIRAI TOSHIAKI
  • SHINMORI HIDEYUKI
  • MOCHIZUKI CHIHIRO
IPC(International Patent Classification)
Specified countries (WO2017119417)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please feel free to contact us by email or facsimile if you have any interests in this patent.

PAGE TOP

close
close
close
close
close
close